Peanut OIT

Phase 2Biologic

UUniversity of North Carolina, Chapel Hill

Peanut OIT is one of 22 biologic programs targeting Allergy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

AllergyPhase 2

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Allergy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Flagyl

DDePuy Orthopaedics

Approved

1 4

Potassium Citrate

MMission Pharmacal

Approved

1 5

Levaquin

WWim Janssens

Approved

1 6

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 7

Allegra

CChattem

Approved

1 8

Claritin

PPerrigo Company

Approved

1 9

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 10

Lastacaft

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunotherapy5 trials

Salvage Peanut Oral Immunotherapy Study

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1/2·NCT03251508·15 enrolled

Tolerance Following Peanut Oral Immunotherapy

Completed·MMassachusetts General Hospital·Phase 1/2·NCT01750879·41 enrolled

A Study of Sublingual Immunotherapy in Peanut-allergic Children

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT00597727·60 enrolled

Show 2 more trials

Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

Completed·JJohns Hopkins University·Phase 2·NCT03345160·7 enrolled

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 1/2·NCT01274429·5 enrolled

Allergy3 trials

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Active, not recruiting·AALK-Abelló A/S·Phase 1/2·NCT05440643·192 enrolled

Oral Immunotherapy for Peanut Allergy (PMIT)

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT00597675·10 enrolled

Oral Immunotherapy (OIT) for Peanut Allergy

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT00815035·16 enrolled

Acute Lymphoblastic Leukemia1 trial

High Threshold Peanut Challenge Study

Completed·MMassachusetts General Hospital··NCT02698033·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Peanut OIT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peanut OIT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peanut OIT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of North Carolina, Chapel Hill

Peanut OIT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunotherapy5 trials

Allergy3 trials

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News